.jpg)
.png)
In October of 2018, the American College of Cardiology (ACC) and the American Heart Association (AHA), in collaboration with the National Lipid Association and other organizations, published evidence-based guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD).(1) Along with the guidelines, there was a Special Report summarizing the rationale and evidence base for the current quantitative risk assessment tools.(2) These newest iterations stre
Article By:
Director, Penn Cardiology Penn Preventative Care Medical Director, Penn Presbyterian Heart and Vascular Pavilion
Associate Professor of Clinical Medicine Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
Fellow-in-Training, Post-Graduate Year 5 Cardiovascular Medicine,
University of Pennsylvania Philadelphia, PA
Cardiovascular disease (CVD) remains the leading cause of death for women in the United States.(1) Unique factors affecting a woman’s health contribute significantly to CVD risk, but historically were not always represented in major guidelines. Some of these factors include hormonal changes, the presence of gender-specific risk factors and comorbidities more frequently seen in women (e.g. rheumatoid arthritis and systemic lupus erythematosus).
Article By:
Internal Medicine
Lenox Hill Hospital
New York, NY
Director, Preventive Cardiology & Lipid Clinic Division of Cardiology
Bassett Medical Center
Cooperstown, NY
Diplomate, American Board of Clinical Lipidology
System Director, Cardiovascular Prevention Northwell Health
Director, Women’s Heart Health
Lenox Hill Hospital
New York, NY
Diplomate, American Board of Clinical Lipidology
Reduced estimated glomerular filtration rate (GFR) and chronic kidney disease (CKD) are also independently associated with the risk of death and cardiovascular (CV) events in community.(3) When compared to the general population, patients with CKD have a distinct lipid profile which involves alterations in different lipoprotein classes and shows considerable variations depending on the stage of CKD.(4) Although very complex, the most important characteristics of this uremic lipid profile can
Article By:
Fellow
NorthShore University Health System Chicago, IL
Director, Lipid Clinic
NorthShore University Health System Clinical Instructor
University of Chicago
Chicago, IL
Diplomate, American Board of Clinical Lipidology
Scientific & Executive Director, Robarts Research Institute Professor, Department of Physiology & Pharmacology Schulich School of Medicine & Dentistry
London, ON
The Midwest Lipid Association Chapter started the fall with our co-sponsored Clinic Lipid Update in Minneapolis in September. It was great to see many familiar NLA member colleagues as well as new attendees.
As part of the MWLA’s goals for this year, we are finalizing a three-year strategic plan. An important step was to create a mission statement.
Article By:
President, Midwest Lipid Association
Faculty, Foundations of Lipidology Course
Founder, Mobile Health Team Lipids Clinic
Adjunct Assistant Professor of Pediatrics, University of Wisconsin School of Medicine and Public Health
Neenah and Wauwatosa, WI
Diplomate, American Board of Clinical Lipidology
Introduction
Elevated cholesterol is a well-known and modifiable risk factor for cardiovascular disease. Hyperlipidemia due to secondary causes is common and should be evaluated as part of treatment. Potential secondary causes include diabetes mellitus, excessive alcohol intake, cholestatic liver disease, hypothyroidism, chronic kidney disease, nephrotic syndrome and various classes of medications.(1)
Article By:
Specialty Practice Pharmacist Ambulatory Care
The Ohio State University
Wexner Medical Center
Columbus, OH
Specialty Practice Pharmacist Ambulatory Care
The Ohio State University
Wexner Medical Center Columbus, OH
Primary Care Pharmacy Specialist
Cleveland Clinic
Cleveland, OH
Director of Preventative Cardiology & Women’s Cardiovascular Health Director of Lipid Clinics
Professor of Medicine
The Ohio State University
Wexner Medical Center Columbus, OH
Diplomate, American Board of Clinical Lipidology
Fabry’s Disease and Morquio A syndrome are two rare genetic diseases that lead to a diverse series of problems including cardiovascular.(1,30) Until recently, treatment options have been limited to treat these conditions. Now that there are available therapies to help improve quality and quantity of life, (20,46) it is important to be able to recognize these conditions in clinical practice to help initiate treatment earlier.
Article By:
Cardiology Fellow-In-Training
University of Chicago (NorthShore) Program Evanston, IL
Director, Lipid Clinic
NorthShore University Health System Clinical Instructor
University of Chicago
Chicago, IL
Results from multiple trials prompted the Food and Drug Administration’s (FDA) approval of empagliflozin (Jardiance) for reducing cardiovascular (CV) death and canagliflozin (Invokana) for reducing CV death and CV events, in patients with cardiovascular disease and type II diabetes (T2D).(1-6) The FDA’s expanded approval of empagliflozin and canagliflozin led to the American College of Cardiology (ACC) and the American Diabetes Association
Article By:
Complex Lipids Clinic
Mobile Health Team
Neenah, WI
Although there is debate over the definition of metabolic syndrome in adults, the picture is even more clouded in pediatrics. Metabolic syndrome in adults is defined as having at least three of the following five cardiometabolic risk factors: hyperglycemia, increased central adiposity, elevated triglycerides, decreased HDL cholesterol and elevated blood pressure.(1) In pediatrics, there have been up to 40 definitions of metabolic syndrome proposed.
Article By:
Department of Pediatrics University of Wisconsin School of Medicine and Public Health Madison, WI
Department of Pediatrics
University of Wisconsin School of Medicine and Public Health
Madison, WI
Diplomate, American Board of Clinical Lipidology
“People who believe they are ignorant of nothing have neither looked for nor stumbled upon the boundary between what is known and unknown in the universe”
— Neil deGrasse Tyson
It is a privilege as the co-editor of the LipidSpin to write the Editor’s Corner for the Midwest (MWLA) edition of the journal.
Article By:
Editor, LipidSpin
Medical Director, Lipid Clinic and Physician Advisor Ascension Wisconsin All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology
While expertise in lipids management has evolved over many decades, our field of lipidology truly took flight in 2006 with the American Board of Clinical Lipidology certification process. Since those early days, we have slowly but steadily raised awareness of the value of the care we provide as lipid specialists. It is likely that each and every one of you has had to explain what a lipid specialist is, or does, more than once in your career.
Article By:
President, Midwest Lipid Association
Faculty, Foundations of Lipidology Course
Founder, Mobile Health Team Lipids Clinic
Adjunct Assistant Professor of Pediatrics, University of Wisconsin School of Medicine and Public Health
Neenah and Wauwatosa, WI
Diplomate, American Board of Clinical Lipidology